Description
Latin name
STOPDIAR
Release form
Film-coated tablets.
Packaging
In a blister pack of 24 tablets, film-coated. In the package 1 blister.
Pharmacological action
Pharmacodynamics
Nifuroxazide is a derivative of 5-nitrofuran. It has a local antibacterial effect in the intestinal lumen against gram-positive bacteria from the genus Staphylococcus and gram-negative bacteria from the family Enterobacteriaceae from the genus: Yersinia sp., Escherichia sp., Citobacter sp., Enterobacter sp., Klebsiella sp., Salmonella sp.
Nifuroxazide does not show the antibacterial effect of the bacterium species: Proteus vulgaris, Proteus mirabilis and Pseudomonas aeruginosa.
Nifuroxazide does not destroy the saprophytic microflora of the digestive tract, does not upset the balance of the normal intestinal flora. It does not cause the appearance of resistant strains. Does not cause the formation of resistant strains. Nifuroxazide inhibits the activity of dehydrogenases and protein synthesis in bacterial cells.
The detailed mechanism of action of the drug is unknown. Nifuroxazide is thought to inhibit dehydrogenase activity and protein synthesis in bacterial cells. Cross resistance to other antibacterial drugs was also not observed.
The effectiveness of nifuroxazide does not depend on the pH existing in the intestinal lumen, or on the sensitivity of microorganisms to antibacterial drugs. The drug is practically not absorbed from the digestive tract, acts exclusively in the intestinal lumen.
Pharmacokinetics
Nifuroxazide is insoluble. After oral administration, it is practically not absorbed from the digestive tract and does not have a systemic effect. It is excreted through the intestines.
Indications
Acute and chronic diarrhea of ² ¹ ² ¹bacterial origin
acute foodborne illness.
Contraindications
Hypersensitivity to the drug component, including other 5-nitrofuran derivatives
, fructose intolerance, glucose-galactose malabsorption syndrome,
sucrose-isomaltase deficiency, children under 7 years of age.
Use during pregnancy and lactation
As a precaution, it is preferable not to use Stopdiar during pregnancy, since there is insufficient clinical data to evaluate the teratogenic or fetotoxic effects of nifuroxazide when used during pregnancy.
With short-term use, breastfeeding is possible.
Composition
1 film-coated tablet contains:
Active substance:
nifuroxazide 100 mg.
Excipients:
silicon dioxide colloidal dioxide (Aerosil hydrophilic 200) 3.0 mg,
potato starch 179.0 mg,
gelatin 11.0 mg,
talc 6.0 mg,
magnesium stearate 1.0 mg.
shell tablets:
hypromellose 3.0 mg,
titanium dioxide 0.252 mg,
talc 0.062 mg,
polyethylene glycol 20,000 0.201 mg,
quinoline yellow dye 0.112 mg.
Dosage and administration of
Stopdiar is recommended for oral administration.
The drug is prescribed for adults and children over 7 years of age, 200 mg (2 tablets) 4 times / day. The drug is taken regardless of food intake at regular intervals (every 6 hours). The course of treatment in prescribed doses is no more than 3 days.
During treatment of acute diarrhea with a drug, continuous oral or intravenous supplementation of fluid deficiency in the body is required, depending on the general condition of the patient.
If after this period the symptoms do not disappear, the patient should consult a doctor. The tablet should be swallowed whole, without chewing, without crushing, washing down with an appropriate amount of water.
Side effects
Nifuroxazide is well tolerated, side effects were practically not observed. In the presence of increased individual sensitivity to nifuroxazide in isolated cases, the following adverse reactions are possible.
From the digestive system: abdominal pain, nausea, increased diarrhea.
From the hemopoietic system: granulocytopenia.
From the side of the skin and subcutaneous fat: skin rash (including pustular), nodular pruritus.
Allergic reactions: shortness of breath, swelling of the face, lips, tongue, skin rash, itching.
Overdose
Symptoms: increased side effects.
Treatment: gastric lavage, symptomatic therapy.
Storage conditions
Store at a temperature of 15 ° C to 25 ° C.
Expiration
4 years.
Active in substance
Nifuroxazide
pharmacy terms and conditions without a prescription
Dosage form
Dosage form
tablets
